The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...

Most of the 38 million people living with diabetes in the U.S. use daily injections or insulin pumps to keep glucose at safe levels — but new research suggests that a third option could be just as ...

Some patients with type 2 diabetes will be able to switch from daily insulin injections to this first-of-its-kind once-weekly ...

Please provide your email address to receive an email when new articles are posted on . A group of experts updated the FITTER insulin injection recommendations for the first time since 2016. The ...

Most diabetes patients must carefully monitor their blood sugar levels and inject insulin multiple times per day, to help ...

For over a century, scientists have chased the dream of insulin pills, but the digestive system kept destroying the drug ...

A small device implanted just beneath the skin, roughly the size of a large postage stamp and weighing about two grams, kept ...

The primary factor behind diabetes is that your body may not make enough insulin (type 1 diabetes) or it fails to respond to the insulin your pancreas releases, which is known as insulin resistance ...

Researchers compared the efficacy of once-weekly and once-daily insulin treatments for type 2 diabetes. They found that the once-weekly treatment icodec was more effective in lowering blood sugar ...

Scientists may be closer to an oral insulin pill after researchers at Kumamoto University developed a DNP peptide that helps ...

(1,2) "Awiqli (R) is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It's helping to reframe what basal ...